EGFR and non-small cell lung carcinoma: In HERTHENA‐Lung01, patritumab deruxtecan was studied in 225 patients with EGFR‐mutated locally advanced or metastatic NSCLC following disease progression with an EGFR‐TKI and platinum‐based chemotherapy, which demonstrated an ORR of 29.8%.